ADVM

Adverum Biotechnologies, Inc. (ADVM) | Rumor.io

Adverum Biotechnologies

ADVM

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ADVM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Dec 9

Adverum Biotechnologies (ADVM) has been acquired by Eli Lilly (LLY) in a tender offer, with the merger completing on December 9, 2025.
ADVM CEO Laurent Fischer purchased 128,699 shares at $4.30 for a total of $553,917, while Chief Operating Officer Peter Soparkar bought 50,000 shares at $4.22.
ADVM shareholders will receive $3.56 and a CVR for each share held at closing, with the stock halted on December 9, 2025, and suspended effective December 10, 2025.

Generated by AI

Sentiment

Of the messages about ADVM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	61.85% -23.67
Bearish	—	—	—	38.15% +23.67

Bullish· Oct 24

Adverum Biotechnologies, Inc. (ADVM) is being acquired by LLY for up to $12.47 per share, with a $3.56 cash payment plus two contingent value rights (CVRs) that can pay up to $8.91.
The acquisition is a significant deal, with a potential total value of up to $1.3 billion, and could result in a payout over time of up to $12 per share.
The stock has a high short interest of 8%, which could lead to a short squeeze and further price appreciation, with some analysts predicting a potential exit point of $45.00.

Bearish· Jul 17

$ADVM is trading at a low price due to shorts manipulation, which may lead to a short squeeze.
The company's 10m float is small, making it susceptible to large price swings and potential volatility.
The stock may be manipulated by market makers or prop firms for short-term gains, leading to artificially low prices.

Generated by AI

Topics

Of the messages about ADVM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	19.2%
Announcements	—	—	—	74.78%
Controversies	—	—	—	0.33%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	5.69%

Earnings· Mar 5

Adverum Biotechnologies, Inc. (ADVM) is releasing its earnings today.
Investors are awaiting the company's earnings release for ADVM.
ADVM's earnings are being reported on this day.

Analysts· Jul 23

Cantor Fitzgerald downgraded Adverum Biotechnologies to Neutral from Overweight, lowering the price target to $3 from $23.
Multiple analysts, including Alethia Young and Mani Foroohar, maintained a Neutral or Market Perform rating for Adverum Biotechnologies, with some lowering their price targets.
Chardan Capital and SVB Leerink also cut their price targets for Adverum Biotechnologies to $3 and $2, respectively.

Announcements· Oct 24

Eli Lilly has agreed to acquire Adverum Biotechnologies in a deal valued at up to $261.7 million.
The acquisition includes a cash payment of $3.56 per share and a contingent value right (CVR) that can pay up to $8.91 per share upon the achievement of certain milestones.
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration, and Lilly will also provide a $65 million promissory note to Adverum to cover ongoing development costs.

Technical Analysis· Apr 29

$ADVM has formed a potential double bottom and may bounce near the 380/385 area.
The stock may have additional downside to $3.30 - $3.60, but watching for entry for a short-term swing.
A dead cat bounce play is possible, with entry at $4.59, $4.61, and a target of $5+.

Generated by AI

Community

Of the messages about ADVM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	35.69%
Newcomers	—	—	100%	64.31%

Regulars· Oct 24

The acquisition of Adverum Biotechnologies by Eli Lilly for up to $261.7 million includes a $3.56 per share cash payment plus contingent value rights worth up to $8.91 per share.
Adverum's gene therapy candidate, Ixo-vec, is the primary focus of the acquisition, with Lilly seeking to tap the eye care market through this deal.
The acquisition price of up to $12.47 per share is a record cash plus CVR ratio, with the stock trading unusually low on the announcement day.

Newcomers· Oct 24

Eli Lilly is acquiring Adverum Biotechnologies for $3.56 per share in cash, with the potential for up to $8.91 per share in a contingent value right (CVR) based on milestones.
The acquisition is part of Lilly's strategy to expand its portfolio in the eye care and gene therapy markets, with a focus on Adverum's lead program, Ixo-vec, a Phase 3 gene therapy for vision loss.
The deal has the potential to pay out over time, with a maximum value of $12.47 per share, but for now, the stock price is around $4.32.

Generated by AI

Also Discussed

Investors talking about ADVM also mention

#	Name	Attention
1	Regenxbio Inc.RGNX	0%+0
2	4D Molecular Therapeutics, Inc.FDMT	0%new
3	Voyager Therapeutics, Inc.VYGR	0%0
4	SYBX - Synlogic, Inc.	——
5	Solid Biosciences Inc.SLDB	0.3%new
6	MRTX - Mirati Therapeutics, Inc.	——
7	Krystal Biotech, Inc.KRYS	0%0
8	ACHL - Achilles Therapeutics plc	——
9	PSTX - Poseida Therapeutics, Inc.	——
10	MeiraGTx Holdings plcMGTX	0%new